Pulse Biosciences (PLSE) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Company Overview, Mission, and Leadership

• Focused on nanosecond pulsed field ablation (nsPFA) as a disruptive, next-generation therapy for large market opportunities, aiming to revolutionize treatment for multiple diseases.

• Leadership team includes experienced technologists, clinicians, and industry veterans, with a strong board and deep medtech expertise.

• Over 10 years of development and $300M invested, with 183 issued and 103 pending patents globally.

• Not seeking acquisition; aims to build a platform company with broad clinical reach.

• Over 80% insider ownership.

Financial and Operational Highlights

• Cash and cash equivalents of $118M at year-end 2024, pro forma $130M including rights offering, with no debt and a multi-year runway.

• Cash burn of $36M in 2024, expected to increase in 2025 for commercialization and clinical trials.

Technology Differentiation and Clinical Advantages

• nsPFA delivers energy in billionths of a second, a thousandfold shorter than microsecond PFA, enabling higher amplitude, deeper, and nonthermal lesions.

• Proprietary console and purpose-built devices allow for software-tunable applications across multiple indications.

• nsPFA avoids nerve capture, reduces anesthesia needs, eliminates thermal injury, and spares critical structures, offering safer, faster, and less invasive procedures.

• Mechanism induces regulated cell death without inflammation or scarring, distinct from microsecond PFA.

• Only company with clinical-stage nanosecond PFA, protected by a robust IP estate.